# POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

> **NCT04826016** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **MedSIR**

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** POL6326
- **DRUG:** Eribulin
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT04826016
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-16
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funder decision
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826016, "POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04826016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*